Selumetinib

5 trials 1 recruiting LOncology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

2 Sponsors

8 Countries

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 1 Phase II: 2 Phase I/II: 1 Phase I (Other): 1

Indications tested

Non-small cell lung cancer 1

Sponsors using this IMP

AstraZeneca AB 4 Istituto Europeo Di Oncologia S.r.l. 1

All trials

5 total

Clinical utility of a next generation sequencing-based “oncochip” for therapeutic decision in metastatic breast cancer. Study SHARP Recruiting

2024-513934-40-00 Phase II 1 country Istituto Europeo Di Oncologia S.r.l.
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged ≥ 1 to < 7 Years with Neurofibromatosis Type 1… Ended

2023-506357-38-00 Phase I/II 3 countries Astrazeneca AB
Efficacy and Safety of Selumetinib in Adults with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromas. Ended

2023-507336-20-00 Phase III 5 countries Astrazeneca AB
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children with Neurofibro… Ended

2024-517216-29-00 Phase I (Other) 1 country AstraZeneca AB
A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu… Ended

2023-504624-25-00 Phase II 5 countries AstraZeneca AB

Showing 1–5 of 5 trials

← All drugs A–Z